No Data
No Data
Hainan Hulwa Pharmaceutical Group (605199.SH): The Shanghai Stock Exchange did not approve the company's application to issue convertible bonds.
Hainan Huluwa Pharmaceutical Group (605199.SH) announced that the Listing Review Committee of the Shanghai Stock Exchange will review the listing in August 2024...
Hainan Huluwa Pharmaceutical Group (605199.SH): Subsidiary obtained the pharmaceutical GMP compliance inspection results.
Hainan Huluwa Pharmaceutical Group (605199.SH) announced that its wholly-owned subsidiary, Guangxi Weiwei Pharmaceutical Co., Ltd., recently received a Notice of Drug GMP Compliance Inspection Results issued by the Guangxi Zhuang Autonomous Region Drug Administration. This GMP compliance inspection covers the liquid intelligent manufacturing center (oral liquid preparation production line) and the 2# normal temperature warehouse at the address of No.10 Fangchenggang Road, Nanning City, Guangxi Weiwei's expansion, and the traditional Chinese medicine pre-processing and extraction workshop at No. 8 Fuxing Road, Laibin City, Guangxi, as well as the liquid intelligent manufacturing center (oral liquid preparation production line) at No. 10 Fangchenggang Road, Nanning City for strong production.
Hainan Huluwa Pharmaceutical Group (605199.SH): Its wholly-owned subsidiary has obtained the registration certificate for the pharmaceutical product of Ibuprofen Suspension.
On August 6th, Gelonhui reported that Hainan Huluwa Pharmaceutical Group (605199.SH), through its wholly-owned subsidiary Guangxi Weiwei Pharmaceuticals Co., Ltd. (referred to as "Guangxi Weiwei"), has recently received the "Drug Registration Certificate" approved and issued by the National Medical Products Administration for ibuprofen suspensions. Ibuprofen suspension is used for fever caused by common cold or influenza in children. It is also used to relieve mild to moderate pain in children, such as headache, joint pain, migraine, toothache, muscle pain, neuralgia, and menstrual pain.
Some Shareholders Feeling Restless Over Hainan Huluwa Pharmaceutical Group Co., Ltd.'s (SHSE:605199) P/E Ratio
Hainan Huluwa Pharmaceutical Group Bronchitis Inhaler Gets NMPA's Approval for Clinical Trials
Hainan Huluwa Pharmaceutical Group (605199.SH): The clinical trial approval notice for Afutelow inhalation solution of tartaric acid has been obtained.
Hainan Huluwa Pharmaceutical Group (605199.SH) announced on July 23 that it has recently received the "Drug Clinical Trial Approval Notice" issued and approved by the National Medical Products Administration regarding the aerosol inhalation solution of afoterol tartrate, authorizing the conduct of clinical trials for the product. Afoterol tartrate aerosol inhalation solution is suitable for the long-term treatment of bronchial constriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
No Data